|本期目录/Table of Contents|

[1]刘晓楠 综述,邸旭 审校.钙化分型在甲状腺癌中的临床病理意义及相关分子机制探讨[J].天津医科大学学报,2024,30(03):277-280.[doi:10.20135/j.issn.1006-8147.2024.03.0277]
点击复制

钙化分型在甲状腺癌中的临床病理意义及相关分子机制探讨(PDF)
分享到:

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:
30卷
期数:
2024年03期
页码:
277-280
栏目:
综述
出版日期:
2024-05-20

文章信息/Info

Title:
-
文章编号:
1006-8147(2024)03-0277-04
作者:
刘晓楠 综述邸旭 审校
(天津市第四中心医院乳腺甲状腺外科,天津300140)
Author(s):
-
关键词:
甲状腺癌钙化分型超声病理分子机制
Keywords:
-
分类号:
R736.1
DOI:
10.20135/j.issn.1006-8147.2024.03.0277
文献标志码:
A
摘要:
钙化是甲状腺癌的重要超声征象之一。近年来对于甲状腺癌钙化的研究逐步深入,对超声中钙化的形态、病理钙盐沉积形式进行了细致分类,钙化的有无、大小、形态和分布与甲状腺癌的临床病理情况密切相关,但钙化形成的分子机制仍然存在争议。本文从钙化分型、显微镜下钙盐沉积形式在甲状腺癌中的临床意义和钙化形成的分子机制3个角度,对钙化在甲状腺癌中的研究进展进行概述。
Abstract:
-

参考文献/References:

[1] SUNG H,FERLAY J,SIEGEL R L,et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2021,71(3):209-249.
[2] TESSLER F N,MIDDLETON W D,GRANT E G,et al. ACR thyroid imaging,reporting and data system (TI-RADS): white paper of the ACR TI-RADS committee[J]. J Am Coll Radiol,2017,14(5):587-595.
[3] CHUNG S R,BAEK J H,CHOI Y J,et al. Diagnostic algorithm for metastatic lymph nodes of differentiated thyroid carcinoma[J]. Cancers (Basel),2021,13(6):1338.
[4] SHIN H S,NA D G,PAIK W,et al. Malignancy risk stratification of thyroid nodules with macrocalcification and rim calcification based on ultrasound patterns[J]. Korean J Radiol,2021,22(4):663-671.
[5] PARK Y J,KIM J A,SON E J,et al. Thyroid nodules with macrocalcification: sonographic findings predictive of malignancy[J]. Yonsei Med J,2014,55(2):339-344.
[6] KOBAYASHI K,FUJIMOTO T,OTA H,et al. Calcifications in thyroid tumors on ultrasonography: calcification types and relationship with histopathological type[J]. Ultrasound Int Open,2018,4(2): E45-E51.
[7] 张毅,袁梅,周亚丽,等. 分化型甲状腺癌超声钙化形态学类型与肿瘤生物学特性及其变异的相关性研究[J].中华超声影像学杂志,2019,28(9):776-781.
[8] NING C P,JI Q L,FANG S B,et al. Distribution patterns of microcalcifications in suspected thyroid carcinoma: a classification method helpful for diagnosis[J]. Eur Radiol,2018,28(6):2612-2619.
[9] YIN L,ZHANG W,BAI W,HE W. Relationship between morphologic characteristics of ultrasonic calcification in thyroid nodules and thyroid carcinoma[J]. Ultrasound Med Biol,2020,46(1):20-25.
[10] 张帅,谷文青,胡传祥,等. 弥漫钙化型甲状腺癌的临床生物学特性研究[J].中华普通外科杂志,2020,35(11):862-865.
[11] PENG Q,ZHANG Q,CHEN S,NIU C. Petal-like calcifications in thyroid nodules on ultrasonography: a rare morphologic characteristic of calcification associated with aggressive biological behavior[J]. Front Endocrinol (Lausanne),2020,11:271.
[12] GWON H Y,NA D G,NOH B J,et al. Thyroid nodules with isolated macrocalcifications: malignancy risk of isolated macrocalcifications and postoperative risk stratification of malignant tumors manifesting as isolated macrocalcifications[J]. Korean J Radiol,2020, 21(5):605-613.
[13] DAS D K,MALLIK M K,HAJI B E,et al. Psammoma body and its precursors in papillary thyroid carcinoma: a study by fine-needle aspiration cytology[J]. Diagn Cytopathol,2004,31(6):380-386.
[14] BAI Y,ZHOU G,NAKAMURA M,et al. Survival impact of psammoma body,stromal calcification,and bone formation in papillary thyroid carcinoma[J]. Mod Pathol,2009,22(7):887-894.
[15] PYO J S,KANG G,KIM D H,et al. The prognostic relevance of psammoma bodies and ultrasonographic intratumoral calcifications in papillary thyroid carcinoma[J]. World J Surg,2013,37(10):2330-2335.
[16] CAI Y F,WANG Q X,NI C J,et al. The clinical relevance of psammoma body and hashimoto thyroiditis in papillary thyroid carcinoma: a large case-control study[J]. Medicine (Baltimore),2015,94(44):e1881.
[17] KIM B K,LEE E M,KIM J H,et al. Relationship between ultrasonographic and pathologic calcification patterns in papillary thyroid cancer[J]. Medicine (Baltimore),2018,97(41):e12675.
[18] JOHANNESSEN J V,SOBRINHO-SIM?簟ES M. The origin and significance of thyroid psammoma bodies[J]. Lab Invest,1980,43(3):287-296.
[19] DAS D K. Psammoma body: a product of dystrophic calcification or of a biologically active process that aims at limiting the growth and spread of tumor[J]. Diagn Cytopathol,2009,37(7):534-541.
[20] ENDO T,OHTA K,KOBAYASHI T. Expression and function of Cbfa-1/Runx2 in thyroid papillary carcinoma cells[J]. J Clin Endocrinol Metab,2008,93(6):2409-2412.
[21] NIU D F,KONDO T,NAKAZAWA T,et al. Transcription factor Runx2 is a regulator of epithelial-mesenchymal transition and invasion in thyroid carcinomas[J]. Lab Invest,2012,92(8):1181-1190.
[22] JIN Y,KIM HK,LEE J,et al. Transcription factor HOXA9 is linked to the calcification and invasion of papillary thyroid carcinoma[J]. Sci Rep,2019,9(1):6773.
[23] WU G,GUO J J,MA Z Y,et al. Correlation between calcification and bone sialoprotein and osteopontin in papillary thyroid carcinoma[J]. Int J Clin Exp Pathol,2015,8(2):2010-2017.
[24] 王军凯,李丽.血清Ⅰ型胶原交联羧基末端肽和骨唾液酸蛋白在甲状腺癌骨转移早期诊断中的临床价值[J].临床与病理杂志,2018,38(7):1429-1433.
[25] 孟晓梅,巴茂文,王绍光,等. BMP-4对甲状腺乳头状癌细胞生物学行为的影响及其分子机制[J]. 山东医药,2021,61(2):1-5.
[26] 金冬春,裴俊烽,竺科英,等. 骨形态发生蛋白-4对甲状腺癌细胞增殖、凋亡和迁移的影响及机制[J]. 中华实验外科杂志,2019, 36(8):1394-1397.
[27] LAMORT A S,GIOPANOU I,PSALLIDAS I,STATHOPOULOS GT. Osteopontin as a link between inflammation and cancer: the thorax in the spotlight[J]. Cells,2019,8(8):815.
[28] FERREIRA L B,TAVARES C,PESTANA A,et al. Osteopontin-a splice variant is overexpressed in papillary thyroid carcinoma and modulates invasive behavior[J]. Oncotarget,2016,7(32):52003-52016.
[29] FERREIRA L B,LIMA R T,BASTOS ACSDF,et al. OPNa overexpression is associated with matrix calcification in thyroid cancer cell lines[J]. Int J Mol Sci,2018,19(10):2990.
[30] FERREIRA L B,ELOY C,PESTANA A,et al. Osteopontin expression is correlated with differentiation and good prognosis in medullary thyroid carcinoma[J]. Eur J Endocrinol,2016,174(4):551-561.

相似文献/References:

[1]王晓宁,贾兰宁,何向辉.甲状腺癌侧颈淋巴结清扫术后并发乳糜漏的比较研究[J].天津医科大学学报,2021,27(03):256.
 WANG Xiao-ning,JIA Lan-ning,HE Xiang-hui.Comparative study of chyle leakage after lateral neck lymph node dissection for thyroid cancer[J].Journal of Tianjin Medical University,2021,27(03):256.

备注/Memo

备注/Memo:
基金项目 天津市卫生健康科技项目(TJWJ2023QN048)
作者简介 刘晓楠(1988-),女,主治医师,博士,研究方向:乳腺甲状腺肿瘤;通信作者:邸旭,E-mail:762693929@qq.com。
更新日期/Last Update: 2024-05-20